✦ LIBER ✦

Pharmacoeconomics of Piperacillin/Tazobactam and Imipenem/Cilastatin in the treatment of patients with intra-abdominal infections

✍ Scribed by Stanford S. Jhee; Mark A. Gill; Albert E. Yellin; Thomas V. Berne; Peter N.R. Heseltine; Maria D. Appleman

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized Comparison of Piperacillin/Ta

✍ Alex A. Erasmo; Armando C. Crisostomo; Lu-Nan Yan; Yun-Sik Hong; Kuhn-Uk Lee; Ch 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Meropenem versus imipenem/cilastatin in

✍ Brismar, B.; Malmborg, A. S.; Tunevall, G.; Lindgren, V.; Bergman, L.; Mentzing, 📂 Article 📅 1995 🏛 Oxford University Press 🌐 English ⚖ 505 KB

Piperacillin/tazobactam compared with ce

✍ Bo Ohlin; Åke Cederberg; Henrik Forssell; Jan Helge Solhaug; Egil Tveit 📂 Article 📅 1999 🏛 Taylor and Francis Group ⚖ 51 KB

PSG12: HOSPITAL COST SAVINGS FROM SEVERI

✍ S Bjerke; R Mallick; K Clark; M Wible; E Zito; R Guttman; G Sillup 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

The treatment of severe intra-abdominal

✍ C. E. Nord 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 441 KB

Piperacillin/Tazobactam vs Imipenem/Cila

✍ D. V. Schmitt; E. Leitner; T. Welte; H. Lode 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 334 KB